Loading
Burkholderia Infections and Melioidosis · Journal article
BMC Infectious Diseases · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case series reports eight patients with culture-negative infections in whom nanopore amplicon sequencing identified pathogens (3 fungi, 5 bacteria) and guided antimicrobial therapy with reported clinical improvement in all cases. The work demonstrates feasibility in a narrow clinical setting but lacks a comparator group, prospective design, or sufficient sample size to establish clinical utility or superiority over existing methods.
Uncontrolled case series. Eight patients with culture-negative infectious diseases including brain abscess, osteoarticular infection, pneumonia, and skin infection; all had at least one underlying disease; specimens collected from infection sites. Intervention: Nanopore amplicon sequencing using MinION device and EPI2ME platform analysis. n = 8.
Eight patients with culture-negative infections enrolled between July 2024 and October 2025 Conventional culture yielded no organisms in any of the eight clinical specimens Nanopore sequencing identified pathogens in all eight cases: fungi in 3 patients, bacteria in 5 patients
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While promising for rapid pathogen detection in culture-negative cases, this case series alone cannot guide clinical practice changes. The results warrant controlled prospective studies comparing nanopore sequencing to conventional and molecular diagnostic standards to establish clinical utility, turnaround time, cost-effectiveness, and impact on patient outcomes.
A small, uncontrolled case series without comparator demonstrating feasibility of nanopore sequencing in culture-negative infections, lacking power to establish clinical efficacy or change practice.
As stated by the source record.
Quoted from the source exactly as published.
While promising for rapid pathogen detection in culture-negative cases, this case series alone cannot guide clinical practice changes. The results warrant controlled prospective studies comparing nanopore sequencing to conventional and molecular diagnostic standards to establish clinical utility, turnaround time, cost-effectiveness, and impact on patient outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Identifying the causative pathogen is essential for selecting optimal antimicrobial therapy, and nanopore amplicon sequencing is an emerging approach for rapid nucleic acid based pathogen detection. This study reports clinical cases in which nanopore sequencing was used alongside conventional culture of clinical specimens obtained from infection sites, aiding clinical decision-making. From July 2024 to October 2025, eight patients with various infectious diseases were enrolled. All patients had at least one underlying disease, and their clinical diagnoses varied, including brain abscess, osteoarticular infection, pneumonia, and skin infection. Specimens, including abscess, ligament, intervertebral disc, joint fluid, sputum, and skin, were collected from infection sites for both routine culture and nanopore sequencing. Conventional cultures yielded no organisms in any of the clinical specimens. Nanopore sequencing was performed using the MinION device, and generated reads were analyzed through the EPI2ME platform. Nanopore amplicon sequencing identified pathogens in culture-negative infections, revealing fungi in three patients and bacteria in five. Targeted antimicrobial therapy based on sequencing led to clinical improvement in all cases. This case series demonstrates the potential utility of nanopore sequencing for detecting pathogens in culture-negative infections. Nanopore sequencing may inform treatment decisions when cultures are negative or are confounded by antibiotics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.